SANOFI EFC17504
The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis.
Inclusion Criteria:
- 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis
- Stable immunomodulatory treatment
- Diagnosed within the last 10 years, without clinical MS relapse or treatment with corticosteroids within last 6 months
What to Expect
Patients will be randomized to receive intravenous frexalimab or placebo up to approximately 51 months administration. A placebo looks like the study drug but contains no real medicine.
For more information click the link below or contact Allison Clarke at aemborsky@dentinstitute.com or 716-558-3543